ClinicalTrials.gg
RecruitingNCT07637825Updated Oct 6, 2026

Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction

An interventional study of Transcranial Focused Ultrasound Neuromodulation and Sham Transcranial Focused Ultrasound Neuromodulation in Ischemic Stroke, sponsored by Jiangsu Taizhou People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Jiangsu Taizhou People's Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 6, 2026Now RecruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
475th of 566
60 · median 271
Started
2026
with 124 others
No phase
247 of 754
122 open now
Primary completion
2027-12
later than 256 of 399 live
Registered
692nd of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 475th largest by planned enrollment of the 566 interventional ones that give a count, is one of 125 that started in 2026, is one of 247 with no phase, reaches primary completion later than 256 of the 399 other live ones, and was the 692nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.

This is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.

Participants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT/MRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.

Statistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Patients with a confirmed imaging diagnosis of first-ever ischemic stroke; (2) Unilateral limb motor involvement; (3) Modified Ashworth Scale (MAS) grade ≤3 for the upper extremity, Brunnstrom stage II-V, and upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60 (inclusive); (4) Age 18-75 years, onset within 21 days to 6 months, in the subacute or recovery phase; (5) Stable vital signs, no consciousness impairment, provided, ability to cooperate with clinical assessments, and approval obtained from the institutional ethics committee.

Exclusion criteria

Exclusion Criteria:

  • (1) to MRI; (2) Infarction involving the thalamus; (3) Risk of intracranial hemorrhage; (4) Presence of intracranial metallic foreign bodies, cardiac pacemakers, or cochlear implants; (5) Unstable medical condition, severe cognitive impairment or psychiatric disorders rendering the patient unable to comprehend the study or cooperate with assessments; (6) Conditions affecting limb motor function, including fractures, joint contractures, or severe limb spasticity; (7) Current use of medications that alter cortical excitability.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Neuromodulation Group

    Multimodal neuromodulation targeting specific neural regions in addition to conventional therapy.

    Device: Transcranial Focused Ultrasound Neuromodulation

  • Sham comparator
    Control Group

    Sham stimulation in addition to conventional therapy.

    Device: Sham Transcranial Focused Ultrasound Neuromodulation

Interventions

  • DeviceTranscranial Focused Ultrasound Neuromodulation

    The transcranial focused ultrasound stimulation device employed in this study is the NeuroFUS DPX-500, equipped with a 4-element transducer array and the BrainSight neuronavigation system. Individualized modeling and target segmentation are performed using high-resolution structural MRI and CT images acquired at baseline. Target planning and neuronavigation are conducted based on intracranial acoustic field simulation. The total stimulation duration is 12 minutes, comprising 480 pulse trains with 0.5 seconds on and 1 second off, yielding a duty cycle of 20%.

  • DeviceSham Transcranial Focused Ultrasound Neuromodulation

    The control group receives sham stimulation during the neuromodulation phase. All procedural steps are identical to those of the experimental group, including neuronavigation positioning, application of coupling gel, and all other preparatory procedures; however, ultrasound stimulation is not activated. Participants in the control group wear bone-conduction headphones to simulate and counteract acoustic confounding. Group allocation information is blinded to participants.

06

What researchers measure

Primary outcomes

  1. Upper extremity Fugl-Meyer Assessment (UE-FMA) motor score

    Upper extremity motor function assessed by the Fugl-Meyer Assessment (motor subscale). Total score ranges from 0 to 66, with higher scores indicating better motor function.

    Time frame: Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)

  2. Resting-state EEG spectral power

    Resting-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

  3. Task-state EEG spectral power

    Task-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

  4. Resting-state fMRI fractional ALFF (fALFF)

    fALFF derived from resting-state functional MRI, the ratio of low-frequency power to whole-frequency power.

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

  5. Resting-state fMRI regional homogeneity (ReHo)

    ReHo (Kendall's coefficient of concordance) from resting-state functional MRI, reflecting local synchronization of neuronal activity.

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

  6. Resting-state fMRI functional connectivity (FC)

    Functional connectivity between regions of interest derived from resting-state functional MRI (Fisher z-transformed correlation coefficients).

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

Secondary outcomes

  1. Brunnstrom recovery stage of the affected upper limb

    Motor recovery staged using the Brunnstrom approach, an ordinal scale from Stage 1 (flaccid, no movement) to Stage 6 (near-normal coordination), with higher stages indicating better motor recovery.

    Time frame: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)

  2. Modified Ashworth Scale (MAS) grade of the affected upper limb

    Muscle spasticity graded with the Modified Ashworth Scale, an ordinal scale with 6 levels (0, 1, 1+, 2, 3, 4); higher grades indicate greater spasticity (a worse outcome).

    Time frame: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)

  3. Fractional anisotropy (FA) on diffusion tensor imaging (DTI)

    White-matter fractional anisotropy measured by diffusion tensor imaging. Dimensionless (0-1), with higher values indicating greater directional coherence of water diffusion.

    Time frame: Baseline (Day 1) and Day 7 (after the 5-day intervention)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent obtained from participants does not include provisions for sharing data outside the research team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 18 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 10, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Mar 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
1 site added, 1 site removed
Show site
  • Taizhou People's Hospital · Taizhou, China
Show 1 removed
  • Harbin Institute of Technology · Harbin, China
Oct 6, 2026
Primary completion
Dec 31, 2026→Dec 31, 2027
Oct 6, 2026
Contact
Study contact changed: z•••@hit.edu.cn · •••8766→z•••@163.com · •••0428. See the current contact
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Taizhou People's Hospital · Taizhou, China
    Show 1 removed
    • Harbin Institute of Technology · Harbin, China
    Primary completion Dec 31, 2026→Dec 31, 2027
    Contact Study contact changed: z•••@hit.edu.cn · •••8766→z•••@163.com · •••0428. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07637825
Lead sponsor
Jiangsu Taizhou People's Hospital
Collaborators
Harbin Institute of Technology
Responsible party
Ming Chu (The deputy dean of the hospital, Jiangsu Taizhou People's Hospital) — Principal investigator
First posted
Jun 10, 2026
Start date
Jun 9, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Gaonian Zhao
Contact
zhaogaonian@163.com
+86 13951170428

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion